S.5043

Secure Drug Supply Chain Act of 2026 aims to prevent unlawful drug imports from China and other adversarial countries.

The Secure Drug Supply Chain Act of 2026 directs the Food and Drug Administration to prevent the importation of counterfeit, unapproved, misbranded, or adulterated drugs from China and other adversarial countries. It mandates the FDA to enhance safeguards for imported drug products, including active pharmaceutical ingredients and key starting materials. The Act also requires the FDA to issue regulations and guidance to ensure compliance with these provisions.